PALO ALTO, Calif., Jan. 29 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that it has licensed a key patent related to nucleic acid delivery technologies in the field of RNAi drug development from Massachusetts Institute of Technology (MIT). The licensing of this intellectual property significantly strengthens Intradigm’s RNAi delivery platform patent portfolio. The scope of the licensed technology covers a broad range of biodegradable polymer structures for the delivery of RNAi therapeutics, thus increasing the opportunity to achieve successful clinical proof of concept. The licensed technology also allows Intradigm to pursue applications for its RNAi NanoPlex(TM) technology across a wider range of therapeutic indications.
“Intradigm’s licensing of this RNAi delivery technology intellectual property is consistent with our commitment to establish a strong IP position that will allow us to identify, develop and commercialize optimal delivery platforms toward the ultimate realization of RNAi therapeutics. This transaction builds on our dominant IP position in the field of biodegradable polymers delivery platform for RNAi therapeutics,” said Mohammad Azab, M.D., president and chief executive officer of Intradigm. “We believe that our licensing of this important intellectual property demonstrates that Intradigm is a key player in the space. We are thrilled to continue our work in the exciting area of RNAi therapeutic development with these new resources at our disposal.”
ABOUT THE RNAi NANOPLEX(TM) DELIVERY PLATFORM
To address the issue of effective and targeted delivery of RNAi therapeutics, Intradigm has developed and in-licensed an extensive intellectual property portfolio around its proprietary RNAi Nanoplex technology, a powerful combination of advanced RNAi delivery systems. In its simplest form, the RNAi Nanoplex technology is comprised of a proprietary, biodegradable polycationic polymer and an active siRNA molecule. The polycationic polymer can also be protected through a steric polymer such as PEG and targeted by attaching a receptor ligand to the nanoparticle. The technology exclusively licensed from MIT enhances Intradigm’s existing intellectual property portfolio and provides Intradigm with the rights and know-how to leverage a broad family of polymers and polymer structures in connection with its RNAi Nanoplex delivery platform.
ABOUT INTRADIGM
Intradigm is a private biotechnology company dedicated to the development of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology.
At present, Intradigm is working to build a high-value internal pipeline of RNAi oncology therapeutics, and is actively advancing its lead drug candidate, ICS-283, for a variety of cancer indications. The company is also establishing collaborative relationships with pharmaceutical and biotechnology companies through which Intradigm’s advanced RNAi delivery technology may be applied to a broad range of therapeutic targets. For more information on Intradigm, please visit http://www.intradigm.com.
CONTACT: Phil Haworth of Intradigm Corporation, +1-650-855-1514,
phaworth@intradigm.com; or investors, Stephanie Diaz , +1-415-675-7400,
sdiaz@vidacommunication.com, or media, Tim Brons, +1-415-675-7402,
tbrons@vidacommunication.com, both of Vida Communication, for Intradigm
Web site: http://www.intradigm.com/
